The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Nicole Martucci - TD Cowen - Analyst
: Okay, great, thank you so much. So let's start off the questions on your 701 program and CML first. So you guys are going to have data later this
year in 4Q, I believe that encompasses longer term efficacy data. What are the general expectations for that? How do you plan on presenting it?
Will it be patient specific like you did the earlier data that you presented, or will it be just overall MMR rates?
Question: Nicole Martucci - TD Cowen - Analyst
: And so moving -- so once you guys move forward, you have plans to evaluate it. Well, you're but you're evaluating the path forward for it to be
either second line or potentially a first line. Is there an option for both of those trials happening at the same time? What is the kind of path of that
look like and what are FDA expectations for that path forward?
Question: Nicole Martucci - TD Cowen - Analyst
: Great. And so there's a lot of different medications on the market for first line, second line, even third line. What drives, what's the biological
reasoning that patients are not responsive to some therapies, and how do you think TERN-701 can really kind of differentiate themselves and
potentially be, both a second line and first line therapy?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 04, 2025 / 7:30PM, TERN.OQ - Terns Pharmaceuticals Inc at TD Cowen Healthcare Conference
Question: Nicole Martucci - TD Cowen - Analyst
: Great, thank you. And so, just kind of a follow up on the molecular responses that you guys have seen. So a deep molecular response encompasses
both a MR4 and an MR5, correct? So is there clinic -- a big clinically meaningful difference between those two? Like is the ultimate goal a MR5 or
is it just in general a deep molecular response?
Question: Nicole Martucci - TD Cowen - Analyst
: Absolutely. And the tolerability issues with the currently approved therapies that you keep mentioning. I guess is that the discontinuations off of
those therapies, is that mainly due to the food effects that you guys don't see, or is it, what exactly is the reasoning behind patients?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 04, 2025 / 7:30PM, TERN.OQ - Terns Pharmaceuticals Inc at TD Cowen Healthcare Conference
Question: Nicole Martucci - TD Cowen - Analyst
: We have a question from the audience.
Unidentified Participant
(inaudible - microphone inaccessible).
Question: Nicole Martucci - TD Cowen - Analyst
: Great, thank you. And so just with the last minute that we have here, I really want to get in a question about the 601 GLP program. So, I would really
love both your thoughts on maintenance dosing for patients, that struggle with obesity and need to lose weight. And how do orals kind of fit into
that paradigm and specifically 601.
Question: Nicole Martucci - TD Cowen - Analyst
: Okay, great. Well, with that we are slightly over time, so thank you guys so much for the presentation.
Question: Nicole Martucci - TD Cowen - Analyst
: Yeah, absolutely, and enjoy the rest of the conference, everyone.
| 
